Page last updated: 2024-12-11
azd 7009
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
AZD 7009: an anti-arrhythmia agent; no further info available 10/2006 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9876235 |
CHEMBL ID | 3545040 |
SCHEMBL ID | 2966851 |
MeSH ID | M0503111 |
Synonyms (16)
Synonym |
---|
azd 7009 |
azd7009 |
864368-79-6 |
DTXSID40235551 |
tert-butyl 2-[7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate |
tert-butyl 2-{7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-di-azabicyclo[3.3.1]non-3-yl}ethylcarbamate |
tert-butyl 2-{7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate |
tert-butyl 2-{7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate |
tert-butyl (2-{7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)carbamate |
JRHUUZPSMQIWBQ-PELRDEGISA-N , |
SCHEMBL2966851 |
CHEMBL3545040 |
AT30351 |
tert-butyl (2-(7-((s)-3-(4-cyanophenoxy)-2-hydroxypropyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl)ethyl)carbamate |
tert-butyl n-[2-[7-[(2s)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]ethyl]carbamate |
AKOS040750667 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 6 (54.55%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (36.36%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |